Comparative Pharmacology
Head-to-head clinical analysis: SULTEN 10 versus TRIPLE SULFAS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULTEN 10 versus TRIPLE SULFAS.
SULTEN-10 vs TRIPLE SULFAS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
Competitive inhibition of dihydropteroate synthase, thereby blocking folate synthesis and bacterial DNA replication. Triple sulfas (sulfadiazine, sulfamerazine, sulfamethazine) act synergistically to inhibit folic acid synthesis.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
1 to 2 tablets (each containing sulfadiazine 167 mg, sulfamerazine 167 mg, sulfamethazine 167 mg) orally every 4 hours initially, then 2 tablets every 6 hours. Maximum daily dose: 6 grams of total sulfonamide.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Terminal elimination half-life ranges from 10-12 hours in adults with normal renal function. Prolonged in renal impairment (up to 24-48 hours) and neonates (40-120 hours).
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Primarily renal; approximately 70-100% excreted unchanged in urine via glomerular filtration and tubular secretion. Minor biliary/fecal elimination (<5%) with enterohepatic circulation possible.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic